Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab Plus Etoposide in Recurrent Malignant Glioma
NCT00612430Phase 2Completed
- Sponsor
- Duke University
- Start
- Mar 2007
- Primary completion
- Sep 2008
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab and etoposide in glioblastoma (GBM) and Gliosarcoma (GS), sponsored by Duke University. Primary endpoint: 6 Month Progression-Free Survival. Started Mar 2007; status: completed.
02
Drugs
bevacizumabetoposide
03
Conditions
glioblastoma (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on NCT00612430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00612430.